Parenteral Drugs (India) (NSE:PDPL) Change In Receivables: ₹0.00 Mil (TTM As of Mar. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) Change In Receivables?

Parenteral Drugs (India) NSE:PDPL 4 Change In Receivables is ₹0.00 Mil as of Mar. 2022. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

Parenteral Drugs (India)'s change in receivables for the quarter that ended in Mar. 2022 was ₹0.00 Mil. It means Parenteral Drugs (India)'s Accounts Receivable stayed the same from Dec. 2021 to Mar. 2022 .

Parenteral Drugs (India)'s change in receivables for the fiscal year that ended in Mar. 2022 was ₹-2.47 Mil. It means Parenteral Drugs (India)'s Accounts Receivable increased by ₹2.47 Mil from Mar. 2021 to Mar. 2022 .

Parenteral Drugs (India)'s Accounts Receivable for the quarter that ended in Mar. 2022 was ₹0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Parenteral Drugs (India)'s Days Sales Outstanding for the three months ended in Mar. 2022 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Parenteral Drugs (India)'s liquidation value for the three months ended in Mar. 2022 was ₹-13,076.28 Mil.

Parenteral Drugs (India)  (NSE:PDPL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Parenteral Drugs (India)'s Days Sales Outstanding for the quarter that ended in Mar. 2022 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/17.731*91
=0.00

2. In Ben Graham's calculation of liquidation value, Parenteral Drugs (India)'s accounts receivable are only considered to be worth 75% of book value:

Parenteral Drugs (India)'s liquidation value for the quarter that ended in Mar. 2022 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.001-13081.419+0.75 * 0+0.5 * 10.274
=-13,076.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Change In Receivables Related Terms

Parenteral Drugs (India) Change In Receivables Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Change In Receivables Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.69 36.65 -35.76 -5.42 -2.47

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of ₹0.00 Mil mean?
Parenteral Drugs (India) (NSE:PDPL) has a Change In Receivables of ₹0.00 Mil as of Mar. 2022. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s Change In Receivables too high?
Parenteral Drugs (India)'s current Change In Receivables is ₹0.00 Mil. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s Change In Receivables compare to ZTS and CTLT?
Parenteral Drugs (India)'s Change In Receivables of ₹0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Parenteral Drugs (India) and its competitors. Parenteral Drugs (India)'s current Change In Receivables is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current Change In Receivables of ₹0.00 Mil. The current Change In Receivables is ₹0.00 Mil. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current Change In Receivables is ₹0.00 Mil as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price